FDA AP — LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% (SUPPL)

FDAmedium relevance

Entity match (hospira)

FDA AP — LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% (SUPPL)

FDAmedium relevance

Entity match (hospira)

FDA AP — LURASIDONE HYDROCHLORIDE (SUPPL)

FDAlow relevance

Weak alignment to signal sub-indication and entities

FDA AP — MILNACIPRAN HYDROCHLORIDE (SUPPL)

FDAlow relevance

Weak alignment to signal sub-indication and entities

FDA AP — MILNACIPRAN HYDROCHLORIDE (SUPPL)

FDAlow relevance

Weak alignment to signal sub-indication and entities

FDA AP — ONDANSETRON HYDROCHLORIDE (SUPPL)

FDAlow relevance

Weak alignment to signal sub-indication and entities

FDA AP — ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE (SUPPL)

FDAlow relevance

Weak alignment to signal sub-indication and entities

Virtual Reality Based High-intensity Interval Training in Chronic Low Back Pain

ClinicalTrials.govhigh relevance

Sub-indication match (pain)

Ondansetron Versus Lidocaine for Preventing Pain on Propofol Injection.

ClinicalTrials.govlow relevance

Weak alignment to signal sub-indication and entities

Effect of Intraoperative Instrumental Music and Operating Room Noise Reduction on Anesthetic and Analgesic Requirements in Pediatric Patients Aged 3-18 Years Undergoing Surgery Under General Anesthesi

ClinicalTrials.govlow relevance

Weak alignment to signal sub-indication and entities

Nurse-Led Telehealth Frailty Management in Older Adults

ClinicalTrials.govlow relevance

Weak alignment to signal sub-indication and entities

Effect of Adrenaline (1:80,000) Containing Local Anesthesia on Glycemic Level of Diabetic and Healthy Individuals Undergoing Tooth Extraction

ClinicalTrials.govlow relevance

Weak alignment to signal sub-indication and entities

Erector Spinae Plane Block Versus Trigger Point Injection for Chronic Thoracic Myofascial Pain

ClinicalTrials.govlow relevance

Weak alignment to signal sub-indication and entities

F-18 Sodium Fluoride PET/CT Guided Versus Ultrasound- Guided Intra-articular Injections in Chronic Low Backache

ClinicalTrials.govlow relevance

Weak alignment to signal sub-indication and entities

FDA Approval Status Update for Lidocaine Hydrochloride 0.4% in Dextrose 5%

Humanexa Signalshigh relevance

Sub-indication match (pain); Entity match (hospira)

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patient

Merckmedium relevance

Sponsor/company relevance (Merck)

[Ad hoc announcement pursuant to Art.

Rochemedium relevance

Sponsor/company relevance (Roche)

FDA Grants AP Status for Doxycycline Hyclate Supplement by Impax Labs

Humanexa Signalslow relevance

Weak alignment to signal sub-indication and entities

Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.

PubMedlow relevance

Weak alignment to signal sub-indication and entities

Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.

PubMedlow relevance

Weak alignment to signal sub-indication and entities

Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.

PubMedlow relevance

Weak alignment to signal sub-indication and entities

Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine.

PubMedlow relevance

Weak alignment to signal sub-indication and entities

' they just take one pill, so it is easy to use, more convenient ': South African health care provider perspectives on Dual Prevention Pill.

PubMedlow relevance

Weak alignment to signal sub-indication and entities